FibroStatin is US-Spain biotech/pharma company developing a treatment that targets drug resistance in lung cancer. A highly specific drug candidate T12 has been developed that inhibits an extracellular kinase which has emerged as a key target to treat and prevent drug resistant and invasive tumors that emerge follow chemotherapy. The company’s technology is covered with 30 patents. The management team has over 96 combined years of experience.